Found: 21
Select item for more details and to access through your institution.
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial.
- Published in:
- Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25905
- By:
- Publication type:
- Article
The Impact of Highly Active Antiretroviral Therapy on Activities of Daily Living in HIV-Infected Adults in South Africa.
- Published in:
- AIDS & Behavior, 2011, v. 15, n. 4, p. 823, doi. 10.1007/s10461-010-9776-y
- By:
- Publication type:
- Article
A Qualitative Assessment of Decisions Affecting Contraceptive Utilization and Fertility Intentions among HIV-Positive Women in Soweto, South Africa.
- Published in:
- AIDS & Behavior, 2009, v. 13, p. 47, doi. 10.1007/s10461-009-9544-z
- By:
- Publication type:
- Article
Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0140623
- By:
- Publication type:
- Article
Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection.
- Published in:
- PLoS ONE, 2015, v. 10, n. 2, p. 1, doi. 10.1371/journal.pone.0118228
- By:
- Publication type:
- Article
CD4 Counts and Viral Loads of Newly Diagnosed HIV-Infected Individuals: Implications for Treatment as Prevention.
- Published in:
- PLoS ONE, 2014, v. 9, n. 3, p. 1, doi. 10.1371/journal.pone.0090754
- By:
- Publication type:
- Article
The Effect of a Maturing Antiretroviral Program on Early Mortality for Patients with Advanced Immune-Suppression in Soweto, South Africa.
- Published in:
- PLoS ONE, 2013, v. 8, n. 11, p. 1, doi. 10.1371/journal.pone.0081538
- By:
- Publication type:
- Article
Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa.
- Published in:
- PLoS ONE, 2011, v. 6, n. 3, p. 1, doi. 10.1371/journal.pone.0017518
- By:
- Publication type:
- Article
Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-Tropic HIV-1 Infection.
- Published in:
- Journal of Infectious Diseases, 2010, v. 201, n. 6, p. 803, doi. 10.1086/650697
- By:
- Publication type:
- Article
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.676980
- By:
- Publication type:
- Article
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 4, p. 560, doi. 10.1093/cid/ciab1037
- By:
- Publication type:
- Article
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 3, p. 425, doi. 10.1093/cid/ciz235
- By:
- Publication type:
- Article
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, n. 8, p. 1322, doi. 10.1093/cid/civ464
- By:
- Publication type:
- Article
Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status.
- Published in:
- 2019
- By:
- Publication type:
- journal article
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis.
- Published in:
- Clinical Infectious Diseases, 2023, v. 77, n. 6, p. 892, doi. 10.1093/cid/ciad301
- By:
- Publication type:
- Article
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 3, p. e580, doi. 10.1093/cid/ciac707
- By:
- Publication type:
- Article
Factors associated with prevalent Mycobacterium tuberculosis infection and disease among adolescents and adults exposed to rifampin-resistant tuberculosis in the household.
- Published in:
- PLoS ONE, 2023, v. 17, n. 3, p. 1, doi. 10.1371/journal.pone.0283290
- By:
- Publication type:
- Article
Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV.
- Published in:
- Southern African Journal of HIV Medicine, 2019, v. 20, n. 1, p. 1, doi. 10.4102/sajhivmed.v20i1.949
- By:
- Publication type:
- Article
An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial.
- Published in:
- PLoS Medicine, 2012, v. 9, n. 6, p. 1, doi. 10.1371/journal.pmed.1001236
- By:
- Publication type:
- Article